Skip to Main Content

On Tuesday, Spark Therapeutics offered what it called “highly encouraging” data in hemophilia A, and Wall Street rewarded it by driving down the stock price by nearly 28 percent.

But doctors in the field say it’s far too early to count Spark out in its effort to craft a gene therapy that could leave patients free of spontaneous bleeding.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!